Unnamed: 0,title,date,stock,sentiment
1406847.0,Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates,2020-06-01 16:00:00-04:00,ZGNX,neutral
1406848.0,"Needham Maintains Buy on Zogenix, Lowers Price Target to $50",2020-05-06 06:35:00-04:00,ZGNX,negative
1406849.0,"Zogenix Q1 EPS $(0.540) Up From $(0.830) YoY, Sales $1.249M May Not Compare To $380.000K Estimate",2020-05-05 16:16:00-04:00,ZGNX,neutral
1406850.0,"The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout",2020-05-05 08:00:00-04:00,ZGNX,positive
1406851.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,ZGNX,neutral
1406852.0,Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.,2020-04-23 11:27:00-04:00,ZGNX,positive
1406853.0,"Mizuho Maintains Buy on Zogenix, Lowers Price Target to $64",2020-04-01 07:48:00-04:00,ZGNX,negative
1406854.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,ZGNX,neutral
1406855.0,"Benzinga's Top Upgrades, Downgrades For March 6, 2020",2020-03-06 09:39:00-05:00,ZGNX,positive
1406856.0,"Citigroup Initiates Coverage On Zogenix with Neutral Rating, Announces $27 Price Target",2020-03-06 05:09:00-05:00,ZGNX,neutral
1406857.0,"The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies",2020-03-04 07:37:00-05:00,ZGNX,negative
1406858.0,A Peek Into The Markets: US Stock Futures Jump Ahead Of Economic Data,2020-03-04 06:19:00-05:00,ZGNX,neutral
1406859.0,Zogenix Prices 8.5M Share Public Offering of Common Stock @$23.50/Share,2020-03-04 05:25:00-05:00,ZGNX,positive
1406860.0,"Zogenix Reports Offering Of Common Stock, No Size Disclosed",2020-03-03 17:08:00-05:00,ZGNX,negative
1406861.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,ZGNX,positive
1406862.0,Zogenix Q4 EPS $(1.26) Misses $(1.06) Estimate,2020-03-02 16:03:00-05:00,ZGNX,negative
1406863.0,"Earnings Scheduled For March 2, 2020",2020-03-02 04:08:00-05:00,ZGNX,neutral
1406864.0,"The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off",2020-02-29 14:52:00-05:00,ZGNX,neutral
1406865.0,"The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO",2020-02-28 07:28:00-05:00,ZGNX,neutral
1406866.0,Stocks That Hit 52-Week Lows On Thursday,2020-02-27 10:23:00-05:00,ZGNX,negative
1406867.0,Zogenix Announces FDA Extension Of Review Period For FINTEPLA In Dravet Syndrome,2020-02-27 08:13:00-05:00,ZGNX,neutral
1406868.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,ZGNX,positive
1406869.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,ZGNX,negative
1406870.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,ZGNX,negative
1406871.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,ZGNX,negative
1406872.0,"Zogenix Disclosed Estimated, Unaudited Cash, Cash Equivalents & Marketable Securities As Of Dec 31, 2019 Were $251.2M",2020-02-13 17:30:00-05:00,ZGNX,positive
1406873.0,"The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology",2020-02-11 07:23:00-05:00,ZGNX,positive
1406874.0,Zogenix Shares Tick Modestly Lower On Uptick In Volume; Hearing Cautious Comments On Stock Given On CNBC,2020-02-10 12:27:00-05:00,ZGNX,negative
1406875.0,Stocks That Hit 52-Week Lows On Monday,2020-02-10 10:28:00-05:00,ZGNX,negative
1406876.0,95 Biggest Movers From Friday,2020-02-10 05:20:00-05:00,ZGNX,neutral
1406877.0,Mid-Afternoon Market Update: Dow Falls Over 300 Points; Assertio Therapeutics Shares Spike Higher,2020-02-07 14:30:00-05:00,ZGNX,positive
1406878.0,"Mid-Morning Market Update: Markets Open Lower; US Adds 225,000 Jobs For January",2020-02-07 10:10:00-05:00,ZGNX,negative
1406879.0,"Benzinga's Top Upgrades, Downgrades For February 7, 2020",2020-02-07 09:50:00-05:00,ZGNX,positive
1406880.0,10 Biggest Price Target Changes For Friday,2020-02-07 08:21:00-05:00,ZGNX,neutral
1406881.0,Zogenix shares are trading lower after Ladenburg Thalmann downgraded the stock from Buy to Neutral and lowered its price target from $60 to $35 per share.,2020-02-07 08:21:00-05:00,ZGNX,positive
1406882.0,"Ladenburg Thalmann Downgrades Zogenix to Neutral, Lowers Price Target to $35",2020-02-07 07:56:00-05:00,ZGNX,negative
1406883.0,16 Healthcare Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:39:00-05:00,ZGNX,neutral
1406884.0,10 Biotechnology Stocks Moving In Friday's Pre-Market Session,2020-02-07 07:35:00-05:00,ZGNX,neutral
1406885.0,"The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns",2020-02-07 07:32:00-05:00,ZGNX,negative
1406886.0,46 Stocks Moving in Friday's Pre-Market Session,2020-02-07 07:25:00-05:00,ZGNX,neutral
1406887.0,29 Stocks Moving In Thursday's After-Hours Session,2020-02-06 17:23:00-05:00,ZGNX,neutral
1406888.0,Zogenix shares are trading lower after the company announced a secondary endpoint in its Phase 3 trial of FINTEPLA did not reach statistical significance.,2020-02-06 16:14:00-05:00,ZGNX,negative
1406889.0,Zogenix Announces Results From Global Pivotal Phase 3 Trial of FINTEPLA For The Treatment Of Lennox-Gastaut Syndrome Met Primary Endpoint; Co. Also Reported FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints,2020-02-06 16:06:00-05:00,ZGNX,positive
1406890.0,Stocks That Hit 52-Week Highs On Friday,2020-01-17 13:23:00-05:00,ZGNX,neutral
1406891.0,"The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares",2020-01-17 08:07:00-05:00,ZGNX,negative
1406892.0,The Lancet Publishes Phase 3 Trial Results for Zogenix  Investigational Drug FINTEPLA in Dravet Syndrome,2019-12-18 05:14:00-05:00,ZGNX,neutral
1406893.0,Zogenix Option Alert: Feb 21 $55 Calls at the Ask: 693 @ $4.75 vs 0 OI; Ref=$47.105,2019-12-10 15:00:00-05:00,ZGNX,positive
1406894.0,"Resideo, Zogenix And More 'Fast Money Halftime Report' Picks For Dec. 6",2019-12-06 07:22:00-05:00,ZGNX,neutral
1406895.0,"Zogenix Reports Will Host Investor Update On FINTEPLA At American Epilepsy Society 2019 Annual Meeting Mon., Dec. 9, 2019",2019-12-05 08:16:00-05:00,ZGNX,neutral
1406896.0,Zogenix Highlights Publication In JAMA Neurology Of Phase 3 Study Of FINTEPLA In Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens,2019-12-02 16:10:00-05:00,ZGNX,neutral
1406897.0,Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.,2019-12-02 11:31:00-05:00,ZGNX,negative
1406898.0,"Zogenix Reports FDA Acceptance For Filing Of New Drug Application, Priority Review For FINTEPLA For Treatment Of Dravet Syndrome",2019-11-25 08:10:00-05:00,ZGNX,positive
1406899.0,"Stifel Nicolaus Maintains Buy on Zogenix, Lowers Price Target to $70",2019-11-08 08:21:00-05:00,ZGNX,negative
1406900.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,ZGNX,negative
1406901.0,Zogenix Announces New Data For Its Investigational Drug FINTEPLA In Dravet Syndrome ; Data Showed Clinically Meaningful Convulsive Seizure Reduction In Patients Under 6 Years Old,2019-10-25 09:02:00-04:00,ZGNX,positive
1406902.0,"Needham Initiates Coverage On Zogenix with Buy Rating, Announces $58 Price Target",2019-10-21 08:50:00-04:00,ZGNX,neutral
1406903.0,Zogenix Presents Positive Clinical Study Results For Investigational Treatment For TK2 Deficiency,2019-10-07 08:09:00-04:00,ZGNX,positive
1406904.0,"The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J",2019-09-26 07:54:00-04:00,ZGNX,positive
1406905.0,Zogenix Reports Submission Of New Drug Application For FINTEPLA For Dravet Syndrome,2019-09-26 07:06:00-04:00,ZGNX,neutral
1406906.0,Zogenix Option Alert: Jan 17 $50 Calls at the Ask: 800 @ $3.3 vs 4922 OI; Earnings 11/7 After Close [est] Ref=$42.26,2019-09-12 13:50:00-04:00,ZGNX,positive
1406907.0,Zogenix Files Prospectus Supplement Relating To Possible Resale Of Other Disposition Of Up To 1.6M Shares,2019-09-10 16:27:00-04:00,ZGNX,positive
1406908.0,'Fast Money Halftime Report' Picks For August 29,2019-08-29 18:25:00-04:00,ZGNX,neutral
1406909.0,50 Biggest Movers From Yesterday,2019-08-27 05:20:00-04:00,ZGNX,neutral
1406910.0,30 Stocks Moving In Monday's Mid-Day Session,2019-08-26 12:40:00-04:00,ZGNX,neutral
1406911.0,"Hearing Stifel Out Defending Zogenix, Unconfirmed",2019-08-26 10:44:00-04:00,ZGNX,negative
1406912.0,Zogenix shares are trading lower after the company announced it would acquire Modis Therapeutics for $175 million in cash and $75 million in Zogenix stock.,2019-08-26 09:48:00-04:00,ZGNX,neutral
1406913.0,Zogenix Will Acquire Modis Therapeutics In $250M Deal,2019-08-26 08:12:00-04:00,ZGNX,neutral
1406914.0,"Zogenix to Acquires Modis Therapeutics for $250M, $175M to be Paid in Cash and $75M in Zogenix Stock",2019-08-26 07:03:00-04:00,ZGNX,neutral
1406915.0,"Zogenix Shares Halted, News Pending",2019-08-26 06:55:00-04:00,ZGNX,positive
1406916.0,Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.,2019-08-19 12:31:00-04:00,ZGNX,positive
1406917.0,"Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.",2019-08-16 13:27:00-04:00,ZGNX,negative
1406918.0,"Zogenix Q2 EPS $(0.89) Misses $(0.78) Estimate, Sales $1.069M Miss $3.7M Estimate",2019-08-06 16:04:00-04:00,ZGNX,negative
1406919.0,"The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering",2019-08-06 07:22:00-04:00,ZGNX,positive
1406920.0,Zogenix Enters Supply Agreement With PCI Pharma Services; PCI To Be The Commercial Manufacturer And Supplier Of Co.'s FINTEPLA,2019-07-23 16:37:00-04:00,ZGNX,positive
1406921.0,Zogenix Completes Enrollment In Phase 3 Trial Of FINTEPLA In Lennox-Gastaut Syndrome,2019-07-08 08:01:00-04:00,ZGNX,neutral
1406922.0,62 Biggest Movers From Yesterday,2019-06-28 05:20:00-04:00,ZGNX,neutral
1406923.0,Hearing Guggenheim Upgraded Zogenix To Buy; Unconfirmed,2019-06-27 14:42:00-04:00,ZGNX,negative
1406924.0,48 Stocks Moving In Thursday's Mid-Day Session,2019-06-27 12:41:00-04:00,ZGNX,neutral
1406925.0,Mid-Morning Market Update: Markets Mostly Higher; Walgreens Earnings Top Views,2019-06-27 10:14:00-04:00,ZGNX,positive
1406926.0,Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application,2019-06-27 10:13:00-04:00,ZGNX,positive
1406927.0,Zogenix shares are trading higher after the company reported an FDA deal to proceed with the resubmission of its FINTEPLA new drug application.,2019-06-27 09:20:00-04:00,ZGNX,positive
1406928.0,Zogenix Reports FDA Deal To Proceed With Resubmission Of FINTEPLA New Drug Application,2019-06-27 08:01:00-04:00,ZGNX,neutral
1406929.0,Zogenix Option Alert: Jul 19 $42 Calls at the Ask: 750 @ $2.3 vs 2349 OI; Ref=$38.,2019-06-05 10:28:00-04:00,ZGNX,positive
1406930.0,"Zogenix Q1 EPS $(0.83), Inline",2019-05-08 16:42:00-04:00,ZGNX,neutral
1406931.0,"'Halftime Report' Traders Share Their View On Zogenix, Spotify And Marvell",2019-04-24 15:43:00-04:00,ZGNX,positive
1406932.0,"The Week In Cannabis News: SAFE Banking Act In The Senate, Greenlane's IPO, B-Real, Canopy Growth And More",2019-04-14 13:23:00-04:00,ZGNX,positive
1406933.0,46 Biggest Movers From Yesterday,2019-04-10 06:27:00-04:00,ZGNX,neutral
1406934.0,38 Stocks Moving In Tuesday's Mid-Day Session,2019-04-09 12:52:00-04:00,ZGNX,neutral
1406935.0,"SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to $48",2019-04-09 11:23:00-04:00,ZGNX,negative
1406936.0,"PiperJaffray Maintains Overweight on Zogenix, Lowers Price Target to $68",2019-04-09 11:18:00-04:00,ZGNX,negative
1406937.0,"Stifel Nicolaus Maintains Buy on Zogenix, Lowers Price Target to $61",2019-04-09 11:03:00-04:00,ZGNX,negative
1406938.0,"Mizuho Maintains Buy on Zogenix, Lowers Price Target to $58",2019-04-09 10:48:00-04:00,ZGNX,negative
1406939.0,Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452,2019-04-09 10:10:00-04:00,ZGNX,negative
1406940.0,"Benzinga's Top Upgrades, Downgrades For April 9, 2019",2019-04-09 09:16:00-04:00,ZGNX,positive
1406941.0,FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy,2019-04-09 09:05:00-04:00,ZGNX,negative
1406942.0,"The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing",2019-04-09 08:10:00-04:00,ZGNX,neutral
1406943.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-04-09 07:59:00-04:00,ZGNX,neutral
1406944.0,Zogenix shares are trading lower after the FDA sent a 'refusal to file letter' to the company for its new drug application for FINTEPLA. Guggenheim downgraded the stock from Buy to Neutral.,2019-04-09 07:49:00-04:00,ZGNX,neutral
1406945.0,A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Job Openings Report,2019-04-09 07:27:00-04:00,ZGNX,negative
1406946.0,Guggenheim Downgrades Zogenix to Neutral,2019-04-09 07:16:00-04:00,ZGNX,neutral
1406947.0,"'$ZGNX conference call…The FDA's RTF letter arrived on Friday. The company says it was their belief that the non-clinical studies now requested by FDA were not necessary, per prior meetings with the agency.' -Tweet From STAT News' Adam Feuerstein",2019-04-08 16:40:00-04:00,ZGNX,neutral
1406948.0,Zogenix shares trading lower after the company announced it received a refusal to file letter from the FDA related to its FINTELPA New Drug Application.,2019-04-08 16:38:00-04:00,ZGNX,neutral
1406949.0,"Zogenix Shares Resume, Down 27%",2019-04-08 16:30:00-04:00,ZGNX,positive
1406950.0,GW Pharma Shares Trading Up 3.9% Following Zogenix News Co. Received Refusal To File Letter From FDA Related To Treatment Of Seizures Related To Dravet Syndrome,2019-04-08 16:09:00-04:00,ZGNX,positive
1406951.0,Zogenix Shares To Resume Trade At 4:30 p.m. EDT,2019-04-08 16:06:00-04:00,ZGNX,positive
1406952.0,Zogenix Receives Refusal To File Letter From US Food And Drug Administration For FINTEPLA New Drug Application,2019-04-08 16:02:00-04:00,ZGNX,neutral
1406953.0,Zogenix Shares Halted News Pending,2019-04-08 16:00:00-04:00,ZGNX,positive
1406954.0,Zogenix Enters Exclusive Distribution Agreement With Nippon Shinyaku For FINTEPLA In Japan,2019-03-19 08:09:00-04:00,ZGNX,positive
1406955.0,Zogenix Q4 EPS $(0.53) Beats $(1.04) Estimate,2019-02-28 16:20:00-05:00,ZGNX,neutral
1406956.0,"The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems",2019-02-28 08:24:00-05:00,ZGNX,positive
1406957.0,"Guggenheim Initiates Coverage On Zogenix with Buy Rating, Announces $70 Price Target",2019-02-22 09:36:00-05:00,ZGNX,neutral
1406958.0,PiperJaffray On Zogenix Expects 'Safety Concerns to be Put to Rest & FDA Approval of Fintepla by Dec 19'; Reiterates Overweight,2019-02-06 13:36:00-05:00,ZGNX,positive
1406959.0,"Zogenix Reports Submission Of New Drug Application, Marketing Authorization Application To FDA, EMA, Respectively, For FINTEPLA Dravet Syndrome Treatment",2019-02-06 08:10:00-05:00,ZGNX,positive
1406960.0,"Zogenix Reports Phase 3 Trial Results On Efficacy, Safety Of FINTEPLA In Dravet Syndrome: Data from Second Pivotal Phase 3 Trial Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA",2018-12-03 09:02:00-05:00,ZGNX,positive
1406961.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs",2018-12-02 17:51:00-05:00,ZGNX,neutral
1406962.0,Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA on Everyday Executive Function in Patients with Dravet Syndrome at AES 2018,2018-12-02 10:04:00-05:00,ZGNX,positive
1406963.0,"Leerink Swann Initiates Coverage On Zogenix with Outperform Rating, Announces $60 Price Target",2018-11-13 08:44:00-05:00,ZGNX,neutral
1406964.0,Zogenix Q2 EPS $(0.82) Up From $(0.90) YoY,2018-11-08 16:02:00-05:00,ZGNX,neutral
1406965.0,"Zogenix Has $3.4B Opportunity With Pediatric Epilepsy Asset, BofA Says In Bullish Initiation",2018-09-14 09:37:00-04:00,ZGNX,positive
1406966.0,"Benzinga's Top Upgrades, Downgrades For September 14, 2018",2018-09-14 09:25:00-04:00,ZGNX,positive
1406967.0,"Bank of America Initiates Coverage On Zogenix with Buy Rating, Announces $63 Price Target",2018-09-14 07:42:00-04:00,ZGNX,neutral
1406968.0,"Northland Securities Initiates Coverage On Zogenix with Outperform Rating, Announces $70 Price Target",2018-09-12 09:18:00-04:00,ZGNX,positive
1406969.0,"Benzinga's Top Upgrades, Downgrades For September 7, 2018",2018-09-07 09:18:00-04:00,ZGNX,positive
1406970.0,A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report,2018-09-07 07:16:00-04:00,ZGNX,neutral
1406971.0,"B. Riley FBR Initiates Coverage On Zogenix with Buy Rating, Announces $116 Price Target",2018-09-07 06:42:00-04:00,ZGNX,neutral
1406972.0,Zogenix Announces Publication Of Phase 2 Study Results Showing ZX008 Provides Durable Reduction In Seizure Frequency In Patients With Lennox-Gastaut Syndrome,2018-09-04 08:09:00-04:00,ZGNX,neutral
1406973.0,Zogenix Highlights Data From 2 Presentations From Sibling Voices Survey,2018-08-30 08:05:00-04:00,ZGNX,neutral
1406974.0,Zogenix Prices 6M Share Common Stock Offering At $52/Share,2018-08-07 18:21:00-04:00,ZGNX,positive
1406975.0,"The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel",2018-08-07 08:23:00-04:00,ZGNX,negative
1406976.0,Zogenix Announces 6M Share Common Stock Offering,2018-08-06 17:14:00-04:00,ZGNX,positive
1406977.0,Zogenix Q2 EPS $(0.83) Up From $(0.90) YoY,2018-08-06 16:28:00-04:00,ZGNX,neutral
1406978.0,38 Biggest Movers From Friday,2018-07-16 04:47:00-04:00,ZGNX,neutral
1406979.0,"Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week",2018-07-13 16:41:00-04:00,ZGNX,positive
1406980.0,"Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering",2018-07-13 08:34:00-04:00,ZGNX,neutral
1406981.0,44 Biggest Movers From Yesterday,2018-07-13 04:08:00-04:00,ZGNX,neutral
1406982.0,Mid-Afternoon Market Update: Dow Up Over 200 Points; Zogenix Shares Gain On Positive Phase 3 Data In Dravet Syndrome Study,2018-07-12 14:31:00-04:00,ZGNX,positive
1406983.0,30 Stocks Moving In Thursday's Mid-Day Session,2018-07-12 12:19:00-04:00,ZGNX,neutral
1406984.0,Mid-Day Market Update: Crude Oil Down Over 1%; IZEA Shares Spike Higher,2018-07-12 12:01:00-04:00,ZGNX,negative
1406985.0,Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Earnings Beat Estimates,2018-07-12 10:26:00-04:00,ZGNX,neutral
1406986.0,Mizuho Raises Zogenix Price Target From $51 To $69,2018-07-12 09:53:00-04:00,ZGNX,neutral
1406987.0,Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study,2018-07-12 08:47:00-04:00,ZGNX,positive
1406988.0,"Zogenix Shares Up 19.4% Premarket After Co. Announced Second Trial Success Of ZX008; Drug Reduced Monthly Convulsive Seizures By Over 50% vs Placebo In Children And Teenagers With Dravet's Syndrome, A Rare And Severe Type Of Epilepsy",2018-07-12 08:42:00-04:00,ZGNX,positive
1406989.0,25 Stocks Moving In Thursday's Pre-Market Session,2018-07-12 08:00:00-04:00,ZGNX,neutral
1406990.0,"UPDATE: Zogenix Says US, EU Regulatory Submission On Track For Q4'18",2018-07-12 07:08:00-04:00,ZGNX,neutral
1406991.0,UPDATE: Zogenix Says ZX008 Demonstrated Statistical Significance In All Key Secondary Endpoints,2018-07-12 07:08:00-04:00,ZGNX,positive
1406992.0,Zogenix Reports Top-Line Results From Second Pivotal Phase 3 Trial Of ZX008 In Dravet Syndrome: Met Primary Endpoint,2018-07-12 07:07:00-04:00,ZGNX,neutral
1406993.0,"Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage",2018-07-10 08:11:00-04:00,ZGNX,positive
1406994.0,"Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium",2018-07-03 07:51:00-04:00,ZGNX,neutral
1406995.0,The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus,2018-06-30 17:32:00-04:00,ZGNX,negative
1406996.0,Zogenix Q1 EPS $(0.87) Beats $(0.90) Estimate,2018-05-09 16:03:00-04:00,ZGNX,neutral
1406997.0,Zogenix Claims ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo,2018-04-27 08:06:00-04:00,ZGNX,positive
1406998.0,"Zogenix Reports Patients on ZX008 Achieved Significant, Clinically Meaningful Reduction in Total Seizure Frequency Compared to Those on Placebo",2018-04-25 08:08:00-04:00,ZGNX,positive
1406999.0,Zogenix Reports Q4 EPS $(1.17) vs $(0.90) Est.,2018-03-06 16:04:00-05:00,ZGNX,neutral
1407000.0,Why Leerink Adjusted Upside Expectations For 3 Biotechs,2018-02-23 11:52:00-05:00,ZGNX,neutral
1407001.0,"Leerink Swann Maintains Outperform on Zogenix, Raises price target to $54.00",2018-02-23 09:48:00-05:00,ZGNX,neutral
1407002.0,Zogenix Reports Receipt Of FDA Breakthrough Designation For ZX008 In Dravet Syndrome,2018-02-06 08:07:00-05:00,ZGNX,neutral
1407003.0,Zogenix Reports Closing Enrollment In Second ZX008 Phase 3 Trial In Dravet Syndrome,2018-01-31 17:02:00-05:00,ZGNX,neutral
1407004.0,Zogenix 8-K Shows Co. $75M Offering Via Selling Holders,2017-12-22 16:05:00-05:00,ZGNX,neutral
1407005.0,32 Biggest Movers From Yesterday,2017-12-05 06:05:00-05:00,ZGNX,neutral
1407006.0,Mid-Afternoon Market Update: Dow Gains Over 200 Points; Astrotech Shares Spike Higher,2017-12-04 14:30:00-05:00,ZGNX,positive
1407007.0,30 Stocks Moving In Monday's Mid-Day Session,2017-12-04 12:24:00-05:00,ZGNX,neutral
1407008.0,Mid-Day Market Update: General Cable Rises Following Acquisition News; Ra Pharmaceuticals Shares Plunge,2017-12-04 12:05:00-05:00,ZGNX,positive
1407009.0,Mid-Morning Market Update: Markets Open Higher; CVS To Buy Aetna For $69B,2017-12-04 10:16:00-05:00,ZGNX,neutral
1407010.0,Zogenix Announces New 'Positive' Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome,2017-12-04 08:02:00-05:00,ZGNX,positive
1407011.0,"As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside",2017-11-27 13:23:00-05:00,ZGNX,neutral
1407012.0,"Benzinga's Top Upgrades, Downgrades For November 27, 2017",2017-11-27 09:05:00-05:00,ZGNX,positive
1407013.0,"JMP Securities Initiates Coverage On Zogenix with Market Outperform Rating, Announces $56.00 Price Target",2017-11-27 08:28:00-05:00,ZGNX,positive
1407014.0,"13F Filing From Baker Bros Shows New Stake In GW Pharmaceuticals, Slight Increase To Ignyta Stake, Exited Stake In Palatin Technologies and Zogenix",2017-11-14 16:01:00-05:00,ZGNX,positive
1407015.0,Zogenix Reports Q3 EPs $(1.68) vs $(0.93) Est.,2017-11-07 16:35:00-05:00,ZGNX,neutral
1407016.0,"Zogenix To Report Q3 Earnings On Tues., Nov. 7 After Market Close",2017-10-31 08:10:00-04:00,ZGNX,neutral
1407017.0,22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency,2017-10-26 15:24:00-04:00,ZGNX,negative
1407018.0,Watch Non-Opioid Pain/Rare Disease Treatment Names Amid Comments From First Lady Trump Related To America's Opioid Crisis,2017-10-26 14:27:00-04:00,ZGNX,negative
1407019.0,Benzinga's Option Alert Recap From October 13,2017-10-13 16:34:00-04:00,ZGNX,positive
1407020.0,Zogenix Option Alert: Nov 17 $39 Puts Sweep (37) at the Bid: 1156 @ $2.801 vs 24 OI; Ref=$39.65,2017-10-13 10:27:00-04:00,ZGNX,positive
1407021.0,25 Stocks Moving In Tuesday's Pre-Market Session,2017-10-10 08:08:00-04:00,ZGNX,neutral
1407022.0,"Zogenix, 10%+ Owner Edelman Buys 300,000 @ Avg Price: $37.50 -Form4",2017-10-03 14:53:00-04:00,ZGNX,neutral
1407023.0,Zogenix Prices 6.7M Share Offering @$37.50/Share,2017-10-02 20:07:00-04:00,ZGNX,positive
1407024.0,What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?,2017-10-02 13:36:00-04:00,ZGNX,neutral
1407025.0,Zogenix Reports 4.3M Share Common Stock Offering,2017-10-02 06:56:00-04:00,ZGNX,positive
1407026.0,"5 Stocks To Watch For October 2, 2017",2017-10-02 05:34:00-04:00,ZGNX,neutral
1407027.0,Mid-Afternoon Market Update: Envirostar Drops After Fiscal 2017 Results; Zogenix Shares Spike Higher,2017-09-29 14:30:00-04:00,ZGNX,positive
1407028.0,Mid-Day Market Update: A10 Networks Gains On Strong Guidance; Louisiana-Pacific Shares Slide,2017-09-29 12:42:00-04:00,ZGNX,positive
1407029.0,Stifel Raises Price Target On Zogenix From $26 To $55 In Mid-Day Note,2017-09-29 12:35:00-04:00,ZGNX,neutral
1407030.0,18 Biggest Mid-Day Gainers For Friday,2017-09-29 12:10:00-04:00,ZGNX,neutral
1407031.0,Mid-Morning Market Update: Markets Mixed; KB Home Profit Beats Estimates,2017-09-29 10:15:00-04:00,ZGNX,positive
1407032.0,Zogenix Offers Slides For Study 1 Phase 3 Top-Line Results Related To Dravet Syndrome Treatment,2017-09-29 08:32:00-04:00,ZGNX,neutral
1407033.0,A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Key Economic Reports,2017-09-29 08:30:00-04:00,ZGNX,neutral
1407034.0,Zogenix's Dravet Syndrome Treatment Returns 'Strong' Results,2017-09-29 08:30:00-04:00,ZGNX,neutral
1407035.0,"Zogenix Shares Resume Trade, Now Up 183%",2017-09-29 07:31:00-04:00,ZGNX,positive
1407036.0,Zogenix Shares To Resume Trade At 7:30 a.m. EDT,2017-09-29 07:06:00-04:00,ZGNX,positive
1407037.0,Adam Feuerstein Tweets: Those $ZGNX study results look strong. 64% average reduction in monthly seizure rate vs. placebo.,2017-09-29 07:06:00-04:00,ZGNX,positive
1407038.0,Zogenix Reports Top-Line Results From Pivotal Phase 3 Trial Of ZX008 In Dravet Syndrome: 'Primary Endpoint Achieved',2017-09-29 07:05:00-04:00,ZGNX,neutral
1407039.0,UPDATE: Zogenix Says 'ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints',2017-09-29 07:03:00-04:00,ZGNX,positive
1407040.0,Zogenix Shares Halted News Pending,2017-09-29 06:57:00-04:00,ZGNX,positive
1407041.0,Downside In Zogenix Shares Intensifies As $13 Support Level Breaks; Stock Down 8.9% For Session,2017-09-28 11:47:00-04:00,ZGNX,positive
1407042.0,"Mizuho Initiates Coverage On Zogenix with Buy Rating, Announces $28.00 Price Target",2017-09-07 07:10:00-04:00,ZGNX,neutral
1407043.0,"Zogenix Reports Q2 EPS $(0.93) vs $(0.89) Est., Sales $7.1M vs $3.48M Est.",2017-08-08 16:30:00-04:00,ZGNX,neutral
1407044.0,"Zogenix Says on August 1, 2017 Terminated License Agreement Dated July 11, 2011 with Durrect Regarding Relday",2017-08-03 06:12:00-04:00,ZGNX,positive
1407045.0,8-K From Zogenix Shows Previously-Announced FDA Granted ZX008 Orphan Drug Designation For Treatment Of LGS,2017-06-22 07:33:00-04:00,ZGNX,positive
1407046.0,Watch These 8 Huge Call Purchases In Friday Trade,2017-06-09 06:32:00-04:00,ZGNX,positive
1407047.0,Benzinga's Option Alert Recap From June 8,2017-06-08 16:08:00-04:00,ZGNX,positive
1407048.0,Option Alert: Zogenix Jul 20.0 Calls: 3000 @  ASK  $0.15: 3000 traded vs 6180 OI:  Earnings 8/9 After Close (est)  $14.50 Ref,2017-06-08 14:39:00-04:00,ZGNX,positive
1407049.0,"Zogenix Reports Q1 EPS $(0.86) vs $(0.88) Est., Sales $2.7M vs $4.23M Est.",2017-05-04 16:54:00-04:00,ZGNX,neutral
1407050.0,Zogenix Completes Enrollment In ZX008 Phase 3 Trial,2017-04-27 08:07:00-04:00,ZGNX,neutral
1407051.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-04-05 08:12:00-04:00,ZGNX,neutral
1407052.0,Mid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares Plunge,2017-03-13 12:37:00-04:00,ZGNX,positive
1407053.0,25 Stocks Moving In Friday's Pre-Market Session,2017-03-10 08:09:00-05:00,ZGNX,neutral
1407054.0,"Zogenix Reports Q4 EPS $(0.95) vs $(0.84) Est., Sales $11M vs $5.24M Est.",2017-03-09 16:02:00-05:00,ZGNX,neutral
1407055.0,Zogenix Receives Orphan Drug Designation in the European Union for ZX008,2017-03-01 08:03:00-05:00,ZGNX,neutral
1407056.0,Zogenix Announces EC Designated ZX008 as Orphan Medicinal Product,2017-03-01 06:35:00-05:00,ZGNX,neutral
1407057.0,Zogenix Shares Up 4.76% In Late-Day Trading; Earlier 13G Filing Showed Perceptive Advisors Reporting 5.46% Stake In Co.,2017-02-22 15:22:00-05:00,ZGNX,positive
1407058.0,"UPDATE: Zogenix Says Safety, Efficacy Portion of 1504, ZX008 Study Expanded from EU to Include Sites in U.S. and Canada",2017-02-13 08:05:00-05:00,ZGNX,positive
1407059.0,"Zogenix Reports Initiation of Clinical Efficacy Portion of Study 1504, ZX008 in Dravet Syndrome",2017-02-13 08:05:00-05:00,ZGNX,neutral
1407060.0,Zogenix Reports Issuance of U.S. Patent for ZX008 in Dravet Syndrome,2017-01-30 08:01:00-05:00,ZGNX,neutral
1407061.0,"Zogenix Announces CFO Transition, Ann Rhoads TO LEave Company, Names Michael Smith CFO",2017-01-05 16:01:00-05:00,ZGNX,negative
1407062.0,Zogenix Reports New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome,2016-12-05 08:02:00-05:00,ZGNX,positive
1407063.0,"Oppenheimer Life Sciences Summit Takes Place Today; Presenters Include Zogenix, Eiger Biopharmaceuticals, And Cellectis",2016-11-29 08:27:00-05:00,ZGNX,neutral
1407064.0,"Aegis Capital Initiates Coverage On Zogenix, Inc. - Common Stock at Buy, Announces $28.00",2016-11-11 11:11:00-05:00,ZGNX,neutral
1407065.0,Hearing Aegis Out Positive On Zogenix,2016-11-11 10:56:00-05:00,ZGNX,positive
1407066.0,"Zogenix Reports Q3 Loss/Share $0.69 vs $0.96 Est Loss/Share, Revenue $6.6M vs $3.1M Est",2016-11-07 16:46:00-05:00,ZGNX,neutral
1407067.0,"Zogenix Reports Q3 EPS $(0.69) vs $(0.96) Est., Sales $6.6M vs $3.1M Est.",2016-11-07 16:03:00-05:00,ZGNX,neutral
1407068.0,Leerink Rates Zogenix Outperform Ahead Of AES Meeting,2016-10-04 12:17:00-04:00,ZGNX,neutral
1407069.0,"Leerink Swann Assumes Zogenix at Outperform, Announces $17.00 PT",2016-10-04 07:13:00-04:00,ZGNX,neutral
1407070.0,Mid-Morning Market Update: Markets Mostly Lower; Michael Kors Issues Downbeat Guidance,2016-08-10 09:56:00-04:00,ZGNX,negative
1407071.0,"Zogenix Reports Q2 EPS $(0.76) vs. Est. $(0.95), Rev. $2.088M vs. Est. $1.3M",2016-08-09 16:29:00-04:00,ZGNX,neutral
1407072.0,Stocks Hitting 52-Week Lows,2016-06-22 10:28:00-04:00,ZGNX,negative
1407073.0,"Zogenix Reports Deal to Refinance Debt, Interest-Only Repayment Provision Results in $10M Increase to Co.'s Expected Cash Balance at End of '17",2016-06-21 08:01:00-04:00,ZGNX,negative
1407074.0,Zogenix Reports Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome,2016-06-07 08:00:00-04:00,ZGNX,neutral
1407075.0,"Zogenix Reports Q1 EPS $(0.42) vs. Est. $(0.62), Rev. $9.2M vs. Est. $4.9M",2016-05-10 16:20:00-04:00,ZGNX,neutral
1407076.0,"Zogenix Reports EPS $(0.42) vs $(0.62) Est., Sales $9.2M vs $4.9M Est.",2016-05-10 16:04:00-04:00,ZGNX,neutral
1407077.0,Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome,2016-05-05 08:23:00-04:00,ZGNX,positive
1407078.0,Mid-Morning Market Update: Markets Mostly Lower; Michaels Tops Q4 Expectations,2016-03-17 10:14:00-04:00,ZGNX,positive
1407079.0,"Brean Capital Positive On Zogenix, Says Favorable Phase 3 Of Cannabidiol Is Positive For ZX008, Sees Potential For Study 504 Read-Out To Yield Support For Premium Pricing & Exclusivity In EU, Maintains Buy And $28 PT",2016-03-15 06:09:00-04:00,ZGNX,positive
1407080.0,"Zogenix Reports Q4 EPS $(0.36) vs $(0.69) Est., Sales $6.1M vs $6.4M Est.",2016-03-10 16:01:00-05:00,ZGNX,neutral
1407081.0,Zogenix Reports Fast Track Designation from FDA for Development of ZX008 in Dravet Syndrome,2016-01-19 08:06:00-05:00,ZGNX,neutral
1407082.0,Zogenix Reports Start of Phase 3 Program for ZX008 in Dravet Syndrome,2016-01-11 08:04:00-05:00,ZGNX,neutral
1407083.0,Zogenix Reports FDA Acceptance of IND App for ZX008 Phase 3 Trial in Dravet Syndrome,2015-12-14 08:09:00-05:00,ZGNX,positive
1407084.0,"8-K from Zogenix Shows New Data Demonstrating Sustained Effectiveness, CV-Related Safety for Patients Treated with ZX008",2015-12-07 16:11:00-05:00,ZGNX,positive
1407085.0,"Zogenix Reports New Efficacy, Safety Data on ZX008 for Seizure Treatment in Dravet Syndrome",2015-12-07 08:03:00-05:00,ZGNX,positive
1407086.0,Mid-Day Market Update: HP Slides Following Q4 Results; Deere Shares Surge,2015-11-25 12:48:00-05:00,ZGNX,positive
1407087.0,Zogenix to Offer New Data on ZX008 for Dravet Syndrome at AAES Meeting,2015-11-25 08:04:00-05:00,ZGNX,neutral
1407088.0,"Zogenix Reports Q3 EPS $(0.65) vs $(0.74) Est., Sales $9.1M vs $5.9M Est.",2015-11-09 16:12:00-05:00,ZGNX,neutral
1407089.0,"Monday's After-Hours Movers: IBM, Sonic, Flextronics And More",2015-10-19 16:43:00-04:00,ZGNX,neutral
1407090.0,UPDATE: Zogenix Says ZX008 Expected to Enter Phase 3 Trials in Q4'15,2015-10-19 16:02:00-04:00,ZGNX,neutral
1407091.0,Zogenix Issues Regulatory Update for ZX008,2015-10-19 16:01:00-04:00,ZGNX,neutral
1407092.0,RA Capital Management Reports 7.5% Passive Stake in Zogenix,2015-10-08 16:25:00-04:00,ZGNX,positive
1407093.0,"Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now",2015-10-06 14:08:00-04:00,ZGNX,neutral
1407094.0,"Shares of Zogenix Spike Nearly 2% Over Last Few Mins, Now In Positive Territory",2015-10-05 13:34:00-04:00,ZGNX,positive
1407095.0,Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial,2015-09-30 08:01:00-04:00,ZGNX,positive
1407096.0,4 More Biotechs Leerink Is Looking At Post-Earnings,2015-08-11 14:26:00-04:00,ZGNX,neutral
1407097.0,"Zogenix Reports Q2 EPS $3.78 may Not Compare, Sales #7.4M vs Est $5.13M",2015-08-10 16:02:00-04:00,ZGNX,neutral
1407098.0,Zogenix Reports 3.8M Share Offering of Common Stock,2015-07-28 16:40:00-04:00,ZGNX,positive
1407099.0,New Alzheimer's Trials Could Produce The Most Important Drugs In History,2015-07-21 15:14:00-04:00,ZGNX,positive
1407100.0,Mid-Day Market Update: Receptos Jumps After Merger News; Marten Transport Shares Slide,2015-07-15 13:03:00-04:00,ZGNX,positive
1407101.0,Mid-Afternoon Market Update: Micron Gains On Rumor Of Tsinghua Bid; Navient Shares Drop,2015-07-14 15:14:00-04:00,ZGNX,positive
1407102.0,UPDATE: Zogenix Sees Co. Submitting IND Application to Begin Phase 3 Trials for ZX008 to FDA During Aug.,2015-07-14 09:20:00-04:00,ZGNX,neutral
1407103.0,"8-K from Zogenix Shows Co. Seeking to Enroll 105 Patients in Each of the Two Planned Double-Blind, Randomized, Controlled Phase 3 Trials for ZX008",2015-07-14 09:19:00-04:00,ZGNX,neutral
1407104.0,Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For $6.3B,2015-07-02 11:05:00-04:00,ZGNX,neutral
1407105.0,"Cantor Analyst: Durect Is Worth $3/Share, So Buy It",2015-06-24 13:53:00-04:00,ZGNX,positive
1407106.0,Zogenix Board Approves 1-for-8 Reverse Split,2015-06-18 16:19:00-04:00,ZGNX,positive
1407107.0,Zogenix Announces New Efficacy Data from Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome,2015-05-27 08:32:00-04:00,ZGNX,neutral
1407108.0,Option Alert: Zogenix Jan 2017 $2.5 Call; 1000 Contract Trade at Ask @$0.40,2015-05-22 15:01:00-04:00,ZGNX,positive
1407109.0,Option Alert: Zogenix Jan 2017 $2.5 Call; 1000 Contract Trade at Ask @$0.40; Now $1.40,2015-05-22 12:08:00-04:00,ZGNX,positive
1407110.0,Option Alert: Zogenix Jan 2017 $2.5 Call; 1000 Contract Trade at Ask @$0.40; Now $1.40,2015-05-19 09:38:00-04:00,ZGNX,positive
1407111.0,"Zogenix Reports Q1 Loss $0.15 Vs Est Loss $0.13, Sales $4.61M Vs Est $8.54M",2015-05-11 16:20:00-04:00,ZGNX,negative
1407112.0,"Zogenix Names Stephen Farr as CEO, Will Continue as Pres",2015-04-27 16:09:00-04:00,ZGNX,neutral
1407113.0,"Empire Asset Management Initiates Coverage on Zogenix at Buy, Announces $5.00 PT",2015-04-13 09:09:00-04:00,ZGNX,positive
1407114.0,Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study,2015-03-26 09:04:00-04:00,ZGNX,neutral
1407115.0,Morning Market Losers,2015-03-11 09:46:00-04:00,ZGNX,negative
1407116.0,Benzinga's Top #PreMarket Losers,2015-03-11 08:17:00-04:00,ZGNX,negative
1407117.0,William Blair Downgrades Zogenix to Market Perform,2015-03-11 06:51:00-04:00,ZGNX,neutral
1407118.0,UPDATE: Zogenix Posts Q4 Loss,2015-03-10 17:19:00-04:00,ZGNX,negative
1407119.0,"PREVIEW: Pernix, Zogenix to Resume Trading at 4:35 PM ET",2015-03-10 16:11:00-04:00,ZGNX,neutral
1407120.0,"UPDATE: Pernix Will Make Upfront Payment Which Includes ~$30M in Cash, $20M in Shares, Zogenix Will Be Eligible for Milestone Payments Up to $283.5M",2015-03-10 16:08:00-04:00,ZGNX,positive
1407121.0,"Zogenix Reports Q4 Loss of $0.14/Share vs Loss of $0.11/Share Est., Sales $14.9M vs $12.74M Est.",2015-03-10 16:06:00-04:00,ZGNX,negative
1407122.0,Pernix Announces Will Acquire Zohydro ER Franchise from Zogenix for ~$100M,2015-03-10 16:05:00-04:00,ZGNX,neutral
1407123.0,Zogenix Shares Halted News Pending,2015-03-10 16:00:00-04:00,ZGNX,positive
1407124.0,"Zogenix Received FDA Approval, Now What?",2015-02-02 13:27:00-05:00,ZGNX,positive
1407125.0,Zogenix Receives FDA Approval Of New Formulation Of Zohydro ER,2015-02-01 11:17:00-05:00,ZGNX,positive
1407126.0,Option Alert: Zogenix Feb $2 Call; 1291 Contract Trade at Ask @$0.10; Now $1.43,2015-01-27 11:43:00-05:00,ZGNX,positive
1407127.0,What Investors Are Watching Ahead of Zogenix's FDA Approval Decision,2015-01-26 13:39:00-05:00,ZGNX,positive
1407128.0,"Zogenix Announces 2014 Guidance, Expects To Have Ended Year With $42.4M Cash",2015-01-12 07:35:00-05:00,ZGNX,neutral
1407129.0,What Investors Should Expect From Rockwell Medical's Next FDA Decision,2015-01-07 16:22:00-05:00,ZGNX,neutral
1407130.0,Zogenix Spikes to High,2014-12-30 15:04:00-05:00,ZGNX,neutral
1407131.0,Brean Capital Initiates Coverage On Zogenix,2014-12-29 16:44:00-05:00,ZGNX,neutral
1407132.0,"Brean Capital Initiates Coverage on Zogenix at Buy, Announces $2.50 PT",2014-12-29 14:51:00-05:00,ZGNX,neutral
1407133.0,"Zogenix Reports Publication of Long-Term Phase 3 Open-Label Study of Safety, Tolerability, Effectiveness of Zohydro(R) ER",2014-12-01 08:34:00-05:00,ZGNX,positive
1407134.0,Purdue Pharma Wins Approval Of An Extended-Release Pure Hydrocodone Painkiller,2014-11-20 13:15:00-05:00,ZGNX,positive
1407135.0,"Events for the Week of Nov. 17-21, 2014",2014-11-17 13:13:00-05:00,ZGNX,neutral
1407136.0,Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products ,2014-10-31 08:36:00-04:00,ZGNX,neutral
1407137.0,"Zogenix Announces Purchase of Brabant Pharma for $20M in Cash, $15M in Shares",2014-10-27 07:31:00-04:00,ZGNX,positive
1407138.0,UPDATE: Zogenix Submits Modified Formulation of Zohydro ER with Potential Abuse Deterrent Properties for FDA Review,2014-10-01 08:39:00-04:00,ZGNX,negative
1407139.0,Zogenix Submits Modified Formulation of Zohydro ER with Potential Abuse Deterrent Properties for FDA Review,2014-10-01 08:31:00-04:00,ZGNX,negative
1407140.0,"8-K from Zogenix Shows Co. Entered Into Third Agreement to License Deal with Daravita: Has Been Granted Exclusive License in US, to Certain IP Rights Related to Hydrocodone Bitartrate",2014-09-18 16:15:00-04:00,ZGNX,positive
1407141.0,New Data From Open Label Study Shows Zohydro ER Reduced Pain and Improved Function in People With Chronic Pain ,2014-09-18 08:33:00-04:00,ZGNX,negative
1407142.0,Zogenix Reports Zohydro ER Shows Sustained 12-Hour Pain Relief,2014-09-02 07:35:00-04:00,ZGNX,negative
1407143.0,"Zogenix, Inc. Reports Q2 EPS of $(0.19) vs $(0.16) Est",2014-08-05 16:05:00-04:00,ZGNX,neutral
1407144.0,"Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix",2014-08-05 14:24:00-04:00,ZGNX,positive
1407145.0,"Zogenix Announces Departure of Chief Commercial Officer, Scott Shively",2014-08-01 16:05:00-04:00,ZGNX,neutral
1407146.0,Zogenix Spikes Lower,2014-08-01 14:23:00-04:00,ZGNX,negative
1407147.0,"Zogenix Announces David Brushwood, J.D., R.Ph., Joins External Safe Use Board",2014-07-17 08:31:00-04:00,ZGNX,positive
1407148.0,"Zogenix Announces Positive Development on US District Court Ruling, Says MA District Court Upholding Prior Decision",2014-07-09 08:30:00-04:00,ZGNX,positive
1407149.0,Massachusetts Must Face Lawsuit Brought By Zogenix Over Painkiller Ban - Bloomberg,2014-07-08 14:22:00-04:00,ZGNX,negative
1407150.0,Morning Market Movers ,2014-07-02 09:38:00-04:00,ZGNX,neutral
1407151.0,Zogenix Provides Update On Development Of Abuse Deterrent Formulations Of Zohydro ER,2014-07-02 07:36:00-04:00,ZGNX,negative
1407152.0,"RF Lafferty & Co. Initiates Coverage on Zogenix, Inc. at Buy, Announces $3.50 PT",2014-06-06 09:22:00-04:00,ZGNX,neutral
1407153.0,"Zogenix Announces Closing of Sale of SUMAVEL DosePro Migraine Therapy to Endo Int'l, Zogenix Repaid $40M in Debt to Healthcare Royalty Partners",2014-05-19 07:33:00-04:00,ZGNX,negative
1407154.0,Benzinga's Top #PreMarket Losers,2014-05-09 08:21:00-04:00,ZGNX,negative
1407155.0,"Zogenix, Inc. Reports Q1 EPS of $(0.20) vs $(0.17) Est; Revenue of $7.67M vs $8.71M Est",2014-05-08 16:19:00-04:00,ZGNX,neutral
1407156.0,Zogenix Reports Inducement Awards Granted,2014-05-02 16:08:00-04:00,ZGNX,positive
1407157.0,"Stifel Nicolaus Maintains Buy on Zogenix, Inc., Lowers PT to $5.00",2014-04-25 07:35:00-04:00,ZGNX,negative
1407158.0,Morning Market Movers ,2014-04-24 09:42:00-04:00,ZGNX,neutral
1407159.0,Benzinga's Top #PreMarket Gainers,2014-04-24 08:11:00-04:00,ZGNX,positive
1407160.0,Zogenix Shares to Resume Trade at 8AM EDT,2014-04-24 07:47:00-04:00,ZGNX,positive
1407161.0,"Zogenix Announces Sale of SUMAVEL DosePro Migraine Therapy to Endo International for $85M, Up to $20M Milestone Payments",2014-04-24 07:31:00-04:00,ZGNX,neutral
1407162.0,Zogenix Halted News Pending,2014-04-24 07:22:00-04:00,ZGNX,neutral
1407163.0,Zogenix Responds to Governor's Action Singling Out Zohydro ER in Massachusetts,2014-04-23 07:34:00-04:00,ZGNX,neutral
1407164.0,Morning Market Movers ,2014-04-16 09:38:00-04:00,ZGNX,neutral
1407165.0,Benzinga's Top #PreMarket Gainers,2014-04-16 08:14:00-04:00,ZGNX,positive
1407166.0,UPDATE: Zogenix-Says Court Granted Temporary Restraining Order Preventing Implementation of Massachusetts Ban of Zohydro ER Extended-Release Capsules =8-K,2014-04-16 06:10:00-04:00,ZGNX,negative
1407167.0,UPDATE: Zogenix Announces Ruling Preventing Implementation of MA. Gov.'s Order Which Prevented Access to Zohydro ER,2014-04-15 16:02:00-04:00,ZGNX,neutral
1407168.0,Zogenix Announces Ruling Preventing Implementation of MA. Gov.'s Order Which Prevented Access to Zohydro ER,2014-04-15 16:00:00-04:00,ZGNX,neutral
1407169.0,"Zogenix Shares Volatile Following Boston Globe Story 'Mass. can't block sale of painkiller, judge rules'",2014-04-15 15:26:00-04:00,ZGNX,positive
1407170.0,Zogenix Files 3-Count Complaint Alleging Massachusetts's Emergency Banning of Zohydro ER is Unconstitutional;  US District Court Allows Zogenix Preliminary Injunction Suspending Enforcement of Ban ,2014-04-15 15:10:00-04:00,ZGNX,negative
1407171.0,Morning Market Movers ,2014-04-09 09:39:00-04:00,ZGNX,neutral
1407172.0,Benzinga's Top #PreMarket Gainers,2014-04-09 08:09:00-04:00,ZGNX,positive
1407173.0,Zogenix Requests Court Order Staying FDA Ban on Zohydro,2014-04-09 05:46:00-04:00,ZGNX,negative
1407174.0,"Zogenix Announces Legal Action in Federal Court Taken, Looking for Injunction on Massachusetts Ban of Zohydro ER",2014-04-07 16:10:00-04:00,ZGNX,negative
1407175.0,Zogenix Says DEA Administrator Stating Misinformation Regarding Zohydro ER ,2014-04-02 22:17:00-04:00,ZGNX,negative
1407176.0,Zogenix Says Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain ,2014-03-28 05:39:00-04:00,ZGNX,negative
1407177.0,Zogenix Appoints James Breitmeyer to Its Board of Directors,2014-03-26 08:30:00-04:00,ZGNX,neutral
1407178.0," Zogenix CEO SaysReports Have Been Including False and Misleading Statements About Company, Product",2014-03-21 12:37:00-04:00,ZGNX,negative
1407179.0,"Morning Losers for Friday, March 14, 2014",2014-03-14 10:10:00-04:00,ZGNX,negative
1407180.0,Benzinga's Top #PreMarket Losers,2014-03-14 08:21:00-04:00,ZGNX,negative
1407181.0,"FDA's Hamburg Defends Approval of Zogenix Zohydro, Says It Is Very Important, 'Unique' Opioid to Treat Pain",2014-03-13 10:00:00-04:00,ZGNX,positive
1407182.0,"Morning Movers for March 12th, 2014",2014-03-12 10:15:00-04:00,ZGNX,neutral
1407183.0,Morning Market Losers ,2014-03-12 09:49:00-04:00,ZGNX,negative
1407184.0,Benzinga's Top #PreMarket Losers,2014-03-12 08:47:00-04:00,ZGNX,negative
1407185.0,Mid-Afternoon Market Update: Fuel Cell Companies Reverse Sharply on Citron Research Report,2014-03-11 16:05:00-04:00,ZGNX,neutral
1407186.0,Zogenix Reports Q4 Earnings; Shares Soar 5%,2014-03-05 18:27:00-05:00,ZGNX,positive
1407187.0,"After-Hours Movers Mar. 5, 2014: ERII, PXLW, BIOD, SEED Higher, DVAX, LYV Lower",2014-03-05 18:15:00-05:00,ZGNX,negative
1407188.0,"Zogenix, Inc. Reports Q4 EPS of $(0.28) vs $(0.09) Est; Revenue of $9.92M vs $8.68M Est",2014-03-05 16:05:00-05:00,ZGNX,neutral
1407189.0,"Earnings Scheduled For March 5, 2014",2014-03-05 04:41:00-05:00,ZGNX,neutral
1407190.0,"Morning Losers for Mar. 3, 2014: YNDX, CETV, AKRX, CPST, LIVE",2014-03-03 10:43:00-05:00,ZGNX,negative
1407191.0,"Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower",2014-02-27 09:43:00-05:00,ZGNX,negative
1407192.0,Human Shows Coverage for Zohydro ER,2014-02-24 09:49:00-05:00,ZGNX,neutral
1407193.0,UPDATE: Zogenix 801 Efficacy Study Met Primary Endpoint,2014-02-13 08:33:00-05:00,ZGNX,neutral
1407194.0,Zogenix Says Study from Zohydro Met Primary Endpoint ,2014-02-13 08:32:00-05:00,ZGNX,neutral
1407195.0,Zogenix Announces Establishment of External Safe-Use Board for Zohydro ER,2014-02-12 14:03:00-05:00,ZGNX,neutral
1407196.0,"Zogenix Offers Update on Zohydro ER, Says Ready for Shipment to Wholesalers, Expecting Commercial Start Early March",2014-02-11 08:39:00-05:00,ZGNX,positive
1407197.0,"Option Alert; Zogenix Jul $5 Call; 2,500 Contract Trade Between Bid and Ask @$0.70; Currently $4.16",2014-02-03 12:48:00-05:00,ZGNX,positive
1407198.0,Benzinga's Top #PreMarket Losers,2014-02-03 08:36:00-05:00,ZGNX,negative
1407199.0,"Zogenix Sees Q4 Gross Product Sales ~$14M, Sees Gross Margin Harmed by $1.3M Charge",2014-01-13 08:34:00-05:00,ZGNX,negative
1407200.0,Zogenix Announces Granting of Inducement Award Under NASDAQ Listing Rule 5635(c)(4),2013-12-20 16:15:00-05:00,ZGNX,positive
1407201.0,Zogenix Names Bradley Galer Chief Medical Officer,2013-12-17 08:32:00-05:00,ZGNX,neutral
1407202.0,Benzinga's Top #PreMarket Gainers,2013-12-17 08:19:00-05:00,ZGNX,positive
1407203.0,"Zogenix Announces Granting of Inducement Wins for Options on 571K Shares, Have Ten-Year Term-Exercise Price ~$3.12/Share",2013-12-11 07:33:00-05:00,ZGNX,positive
1407204.0,Zogenix Announces FDA Approval of 4mg SUMAVEL DosePro Needle-Free Delivery System,2013-12-10 08:31:00-05:00,ZGNX,positive
1407205.0,Benzinga's Top Upgrades ,2013-11-14 08:22:00-05:00,ZGNX,positive
1407206.0,Benzinga's Top #PreMarket Gainers,2013-11-14 08:11:00-05:00,ZGNX,positive
1407207.0,UPDATE: Oppenheimer Upgrades Zogenix Following Zohydro Approval,2013-11-14 07:09:00-05:00,ZGNX,positive
1407208.0,"Oppenheimer Upgrades Zogenix, Inc. to Outperform, Announces $5.00 PT",2013-11-14 06:20:00-05:00,ZGNX,neutral
1407209.0,Zogenix Prices 26.66M Share Offering at $2.25/Share,2013-11-05 19:52:00-05:00,ZGNX,positive
1407210.0,Benzinga's Top #PreMarket Losers,2013-11-04 08:37:00-05:00,ZGNX,negative
1407211.0,US Stock Futures Up Ahead Of Factory Orders Data,2013-11-04 07:30:00-05:00,ZGNX,neutral
1407212.0,Zogenix Announces $60M Common Stock Offering,2013-11-04 07:08:00-05:00,ZGNX,neutral
1407213.0,UPDATE: Stifel Upgrades Zogenix Following Approval of Zohydro,2013-10-29 09:11:00-04:00,ZGNX,positive
1407214.0,"Stifel Nicolaus Upgrades Zogenix, Inc. to Buy, Announces $5.00 PT",2013-10-29 08:15:00-04:00,ZGNX,neutral
1407215.0,"William Blair Raises Price Target from $3 to $6, Maintains Outperform",2013-10-28 08:48:00-04:00,ZGNX,neutral
1407216.0,Benzinga's Top #PreMarket Gainers,2013-10-28 08:14:00-04:00,ZGNX,positive
1407217.0,Zogenix Shares Rise 17% Pre-Market; May be Attributed to $6 PT from William Blair,2013-10-28 07:29:00-04:00,ZGNX,positive
1407218.0,Zogenix Wins FDA Approval for Zohydro ER Capsules,2013-10-25 17:01:00-04:00,ZGNX,positive
1407219.0,"Zogenix Shares Resume, Now at $3.20",2013-10-25 13:13:00-04:00,ZGNX,positive
1407220.0,Shares of Zogenix to Resume Trade at 1:13PM EDT,2013-10-25 13:11:00-04:00,ZGNX,positive
1407221.0,Zogenix Trading Halted,2013-10-25 13:08:00-04:00,ZGNX,neutral
1407222.0,"FDA Approves Extended Release, Single-Entity Hydrocodone Product",2013-10-25 13:08:00-04:00,ZGNX,positive
1407223.0,Zogenix Spikes Higher,2013-10-25 13:07:00-04:00,ZGNX,neutral
1407224.0,Morning Market Movers ,2013-10-02 09:59:00-04:00,ZGNX,neutral
1407225.0,UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic,2013-09-10 12:07:00-04:00,ZGNX,neutral
1407226.0,FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers,2013-09-10 12:04:00-04:00,ZGNX,neutral
1407227.0,Zogenix Shares Moving Higher; May be Attributed to 12:45PM ET FDA Announcement,2013-09-10 10:56:00-04:00,ZGNX,positive
1407228.0,"Zogenix, Inc. Reports Q2 EPS of $(0.13) vs $(0.15) Est",2013-08-08 16:27:00-04:00,ZGNX,neutral
1407229.0,UPDATE: Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal Nasal Spray,2013-06-27 11:25:00-04:00,ZGNX,positive
1407230.0,Zogenix and Valeant in Pact for Migranal Nasal Spray,2013-06-27 11:17:00-04:00,ZGNX,neutral
1407231.0,Zogenix Unveils Improved Migraine Toolbox,2013-06-25 07:34:00-04:00,ZGNX,positive
1407232.0,ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM),2013-06-24 15:16:00-04:00,ZGNX,positive
1407233.0,UPDATE: Oppenheimer Assumes Zogenix at Perform on Fair Valuation,2013-06-21 08:54:00-04:00,ZGNX,positive
1407234.0,"Oppenheimer Reinstates Perform on Zogenix, Inc.",2013-06-20 16:18:00-04:00,ZGNX,neutral
1407235.0,Afternoon Market Losers,2013-06-05 15:40:00-04:00,ZGNX,negative
1407236.0,"Zogenix Announces Plans to Hit Business Milestones, Confirms Cutting of 55 Employees",2013-06-05 08:06:00-04:00,ZGNX,negative
1407237.0,"Form 8-K from Zogenix Showing Co. Cutting Headcount by 55 Employees, Expecting $1M Charge",2013-06-04 17:22:00-04:00,ZGNX,negative
1407238.0,Zogenix-Battelle to Issue New Positive Data for Dosepro,2013-05-20 07:35:00-04:00,ZGNX,positive
1407239.0,"Zogenix, Inc. Reports Q1 EPS of $(0.17) vs $(0.14) Est; Revenue of $6.98M vs $9.28M Est",2013-05-09 16:25:00-04:00,ZGNX,neutral
1407240.0,Zogenix Shares Plunge as FDA Bans Generic Versions of Purdue's Older OxyContin; Wells Fargo Says Zogenix May Benefit from News,2013-04-17 09:14:00-04:00,ZGNX,positive
1407241.0,Zogenix Spikes Lower,2013-04-05 15:13:00-04:00,ZGNX,negative
1407242.0,"Zogenix, Inc. Reports Q4 EPS of $(0.16) vs $(0.17) Est; Revenue of $9.50M vs $9.87M Est",2013-03-15 07:32:00-04:00,ZGNX,neutral
1407243.0,US Stock Futures Slightly Lower Ahead Of CPI,2013-03-15 06:09:00-04:00,ZGNX,negative
1407244.0,"Earnings Scheduled For March 15, 2013",2013-03-15 05:00:00-04:00,ZGNX,neutral
1407245.0,UPDATE: Brinson Patrick Initiates Zogenix at Market Putperform on Zophydro Prospects,2013-03-05 07:30:00-05:00,ZGNX,positive
1407246.0,"Brinson Patrick Initiates Coverage on Zogenix, Inc. at Market Outperform, Announces $5.00 PT",2013-03-05 06:12:00-05:00,ZGNX,neutral
1407247.0,"Benzinga's Small Cap Movers for Wednesday February 27, 2013",2013-02-27 18:28:00-05:00,ZGNX,neutral
1407248.0,"Zogenix Unlikely to Receive Action Letter for NDA for Zohydro ER by PDUFA Goal Date of March 1, 2013",2013-02-26 20:34:00-05:00,ZGNX,neutral
1407249.0,Zogenix Files $75M Mixed Securities Shelf,2013-01-07 09:29:00-05:00,ZGNX,positive
1407250.0,"Zogenix Sees Q4 Sales of $13.4M, Unit Volume Up 9% QoQ; Cited Effect from Hurricane Sandy",2013-01-07 07:39:00-05:00,ZGNX,neutral
1407251.0,Zogenix Announces Positive Relday Phase 1 Clinical Trial Results,2013-01-03 07:40:00-05:00,ZGNX,positive
1407252.0,Zogenix Shares Rally as FDA Redschedules Hydrocodone Drugs Panel,2012-12-18 16:03:00-05:00,ZGNX,positive
1407253.0,UPDATE: Stifel Nicolaus Downgrades Zogenix to Hold Following FDA Panel  ,2012-12-10 11:07:00-05:00,ZGNX,neutral
1407254.0,UPDATE: Oppenheimer Downgrades Zogenix to Perform Following Negative Panel  ,2012-12-10 10:21:00-05:00,ZGNX,negative
1407255.0,Morning Market Losers,2012-12-10 10:02:00-05:00,ZGNX,negative
1407256.0,"Stifel Nicolaus Downgrades Zogenix, Inc. to Hold, Removes $6.00 PT",2012-12-10 08:54:00-05:00,ZGNX,neutral
1407257.0,Zogenix Shares Fall 43% Pre-Market Following Failure to Get FDA Panel OK on Zohydro,2012-12-10 07:50:00-05:00,ZGNX,positive
1407258.0,"Oppenheimer Downgrades Zogenix, Inc. to Perform, Removes $3.00 PT",2012-12-10 06:00:00-05:00,ZGNX,neutral
1407259.0,Zogenix's Zohydro Fails to Win FDA Panel Backing,2012-12-07 16:37:00-05:00,ZGNX,positive
1407260.0,FDA Panel Says Zogenix's Zohydro Unsafe for Intended Patients,2012-12-07 15:30:00-05:00,ZGNX,neutral
1407261.0,FDA Panel Says Zogenix's Zohydro Effective for Chronic Pain,2012-12-07 14:52:00-05:00,ZGNX,negative
1407262.0,"Zogenix to Host Conference Call Following FDA Panel Meeting, Will Be at 6:30PM",2012-12-07 07:40:00-05:00,ZGNX,neutral
1407263.0,Zogenix Halted Ahead of FDA Panel,2012-12-07 07:05:00-05:00,ZGNX,neutral
1407264.0,Zogenix Announces New Chief Commercial Officer ,2012-11-26 07:35:00-05:00,ZGNX,neutral
1407265.0,Zogenix Names R. Scott Shively as New Chief Commercial Officer,2012-11-26 07:35:00-05:00,ZGNX,neutral
1407266.0,Zogenix Says FDA Panel Will Review Zohydro on Dec. 7th,2012-11-08 09:30:00-05:00,ZGNX,neutral
1407267.0,Stocks Hitting 52-Week Highs,2012-10-04 10:07:00-04:00,ZGNX,neutral
1407268.0,UPDATE: Stifel Nicolaus Reduces PT to $6 on Zogenix on Dilutive Deal  ,2012-08-09 11:40:00-04:00,ZGNX,neutral
1407269.0,"Stifel Nicolaus Maintains Zogenix at Buy, Lowers PT from $7 to $6",2012-08-09 08:38:00-04:00,ZGNX,negative
1407270.0,"Oppenheimer Maintains Zogenix at Outperform, Lowers PT from $4 to $3",2012-08-09 06:47:00-04:00,ZGNX,negative
1407271.0,Zogenix Reports Q2 EPS $-0.26 vs $-0.28 Est; Revenues $$8.03 vs $8.79M Est,2012-08-08 16:08:00-04:00,ZGNX,neutral
1407272.0,Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock  ,2012-07-23 16:13:00-04:00,ZGNX,neutral
1407273.0,Zogenix Pops on FDA Acceptance for Review of Zohydro ER NDA,2012-07-16 11:13:00-04:00,ZGNX,positive
1407274.0,"Benzinga's Microcap Movers for Friday July 13, 2012",2012-07-14 16:23:00-04:00,ZGNX,neutral
1407275.0,Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia ,2012-07-12 07:30:00-04:00,ZGNX,neutral
1407276.0,"Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL DosePro",2012-06-07 07:31:00-04:00,ZGNX,positive
1407277.0,"Benzinga's Microcap Movers for Wednesday May 30, 2012",2012-05-30 21:28:00-04:00,ZGNX,neutral
1407278.0,Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM) ,2012-05-30 07:32:00-04:00,ZGNX,neutral
1407279.0,Zogenix Reports Q1 EPS $-0.16 vs $-0.14 Est; Revenues $18.4M vs $17.14M Est,2012-05-14 16:02:00-04:00,ZGNX,neutral
1407280.0,Zogenix and Battelle Ink Marketing Agreement for DosePro Drug Delivery Technology  ,2012-03-29 07:31:00-04:00,ZGNX,positive
1407281.0,Zogenix and Battelle Ink Marketing Agreement for DosePro Drug Delivery Technology ,2012-03-29 07:30:00-04:00,ZGNX,positive
1407282.0,UPDATE: Stifel Nicolaus Cuts PT to $7 on Zogenix ,2012-03-09 13:19:00-05:00,ZGNX,negative
1407283.0,"Stifel Nicolaus Maintains Zogenix at Buy, Lowers PT from $8 to $7",2012-03-09 08:07:00-05:00,ZGNX,negative
1407284.0,Zogenix Reports Q4 EPS $-0.36 vs $-0.34 Est; Revenues $7.9M vs $10.03M Est,2012-03-08 16:10:00-05:00,ZGNX,neutral
1407285.0,Zogenix Files for $75M Mixed Security Shelf,2012-02-03 16:07:00-05:00,ZGNX,positive
1407286.0,Zogenix Trading 12.7% Higher on Heavy Volume; Currently at $2.75,2012-01-26 13:14:00-05:00,ZGNX,neutral
1407287.0,Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology  ,2012-01-25 07:31:00-05:00,ZGNX,positive
1407288.0,"Microcap Movers for Wednesday December 28, 2011",2011-12-28 22:21:00-05:00,ZGNX,neutral
1407289.0,Earlier Rise in Zogenix Due to Reports of Stonger Vicodin Substitute,2011-12-28 11:50:00-05:00,ZGNX,neutral
1407290.0,UPDATE: Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL DosePro,2011-12-21 07:38:00-05:00,ZGNX,positive
1407291.0,"Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL DosePro Effective March 31, 2012 ",2011-12-21 07:32:00-05:00,ZGNX,positive
1407292.0,Zogenix Completes Zohydro Pre-NDA Meetings With FDA,2011-12-20 07:31:00-05:00,ZGNX,neutral
1407293.0,UPDATE: Oppenheimer Lowers PT to $4 on Zogenix ,2011-11-11 08:17:00-05:00,ZGNX,negative
1407294.0,Oppenheimer Lowers PT on Zogenix to $4,2011-11-11 06:49:00-05:00,ZGNX,negative
1407295.0,Zogenix Achieves Zohydro Long-Term Safety Database for NDA ,2011-09-30 07:31:00-04:00,ZGNX,positive
1407296.0,UPDATE: Zogenix Lowers Price Target on Zogenix to $5,2011-09-26 08:00:00-04:00,ZGNX,negative
1407297.0,Oppenheimer Lowers PT on Zogenix to $5,2011-09-26 06:53:00-04:00,ZGNX,negative
1407298.0,Zogenix Spiking Higher on Heavy Volume,2011-09-20 14:52:00-04:00,ZGNX,neutral
1407299.0,Zogenix Prices 30M Share Public Offering at $2.00/Share,2011-09-16 07:30:00-04:00,ZGNX,positive
1407300.0,Zogenix Files Statement for Follow-On Offering of 12M Shares,2011-08-24 09:53:00-04:00,ZGNX,positive
1407301.0,Zogenix Files Registration Statement for Proposed Follow-On Offering,2011-08-24 07:30:00-04:00,ZGNX,neutral
1407302.0,Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint,2011-08-17 07:30:00-04:00,ZGNX,positive
1407303.0,Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain,2011-08-16 17:45:00-04:00,ZGNX,negative
1407304.0,Zogenix Reports Q2 EPS $(0.56) vs $(0.52) Est,2011-08-10 16:24:00-04:00,ZGNX,neutral
1407305.0,Zogenix Reports Q2 EPS $(0.56) vs $(0.52) Est; Revenues $10.2M vs $11.13M Est			,2011-08-10 16:02:00-04:00,ZGNX,neutral
1407306.0,Zogenix Closes $30 Million Royalty Financing With Cowen Healthcare Royalty Partners II,2011-07-18 16:32:00-04:00,ZGNX,neutral
1407307.0,Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro Delivery System and DURECT's SABER Depot Technology,2011-07-12 07:33:00-04:00,ZGNX,neutral
